Cargando…

Correction: Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347439/ https://www.ncbi.nlm.nih.gov/pubmed/37419512 http://dx.doi.org/10.1136/jitc-2022-005132corr1

Ejemplares similares

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Publicado: (2015)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
por: Blot, Mathieu, et al.
Publicado: (2021)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Correction: Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
Publicado: (2022)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
por: Nishio, Makoto, et al.
Publicado: (2023)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Correction: Expression of IL-27 by Tumor Cells in Invasive Cutaneous and Metastatic Melanomas
por: Gonin, Julie, et al.
Publicado: (2013)

Correction: FRIZZLED7 Is Required for Tumor Inititation and Metastatic Growth of Melanoma Cells
por: Tiwary, Shweta, et al.
Publicado: (2017)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Correction: Low Serum High Density Lipoprotein Cholesterol Concentration is an Independent Predictor for Enhanced Inflammation and Endothelial Activation
por: Wan Ahmad, Wan Nor Hanis, et al.
Publicado: (2015)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration
por: Ryu, Dae Gon, et al.
Publicado: (2021)

Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
por: Omata, Wataru, et al.
Publicado: (2022)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
por: Oprea, Adela-Raluca, et al.
Publicado: (2022)

Regression of Multiple Melanocytic Nevi in Two Patients on Nivolumab for Metastatic Melanoma
por: Baeza-Hernández, Gloria, et al.
Publicado: (2023)

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
por: Samonis, George, et al.
Publicado: (2022)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2021)

Correction: Serum 25-hydroxyvitamin D concentrations in dogs with gallbladder mucocele
por: Jaffey, Jared A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_accvsdfukmvnae77upov6vfj1s